Agilent Technologies, Inc. (A) Stock: Price, Forecast & Analyst Target
Agilent Technologies, Inc. (A) — MoonshotScore 84/100 (Exceptional band), calculated Oct 4, 2026. Price $167.77 (+0.65%), as of the Oct 2, 2026 trading session; market cap $47.4B. Expected results Nov 23, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Agilent Technologies, Inc. · A · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Agilent Technologies equips laboratories with analytical instruments, diagnostics and genomics tools, then supports their operation through CrossLab consumables and services. Its economics therefore depend on both laboratory investment and continuing use of installed workflows. Recent growth and profit expansion make demand durability—and the timing of management’s anticipated reshoring benefit—the key issue to follow.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Agilent Technologies (A)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and durable growth, though the balance sheet is only decent; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $1.88B (Q3 FY2026, quarter ended Jul 2026)
- EPS beat 5 of 8
- expected results Nov 23, 2026
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 83 | Exceptional | |
| 85 | Exceptional | |
| 85 | Exceptional | |
| 85 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional |
The score was 84 in the stored Oct 3, 2026 snapshot and remains 84 in the current publication computed Oct 4, 2026 (0). This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $167.77 | |
| Change on the day | +0.65% | |
| 52-week range | $108.35–$177.05 | |
| Market capitalisation | $47.4B | |
| Price / earnings (trailing) | 32.85 | |
| Shares traded on the day | 2.09M | |
| Beta (volatility vs the S&P 500) | 1.24 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Agilent Technologies (A): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 29, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 4, 2026, except a card that shows its own read date.
Watch the A film — every key number, told as a short cinematic story
~2 min · open the film
What is Agilent Technologies (A), and what does it report?
Short answer · as of
Agilent is not simply a diagnostics company. It sells chromatography, mass spectrometry, spectroscopy and cell-analysis systems to life-science and applied-markets laboratories; diagnostics and genomics products span tissue staining, genetic analysis, sequencing preparation and custom oligonucleotides.
Research dated 2026-09-12.
Agilent is not simply a diagnostics company. It sells chromatography, mass spectrometry, spectroscopy and cell-analysis systems to life-science and applied-markets laboratories; diagnostics and genomics products span tissue staining, genetic analysis, sequencing preparation and custom oligonucleotides. CrossLab adds columns, sample-preparation supplies, software, compliance support, asset management and laboratory services.
Reported revenue consequently blends instrument purchases with consumables and service activity tied to laboratory operations. CrossLab is the largest disclosed segment, making recurring laboratory support economically important alongside demand for new systems.
What do the latest results show for Agilent Technologies (A)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $1.88B.
Research dated 2026-09-12.
Revenue, gross profit and operating profit have risen sequentially across the latest reported periods, while net income and diluted earnings also recovered from the recent low. The latest result exceeded revenue and earnings expectations, extending the improvement seen in the preceding report after an earlier shortfall.
The statements show the recovery but do not isolate its operating cause. Management raised its fiscal revenue outlook and said pharma reshoring should begin producing more meaningful orders around year-end, with revenue building later; that frames reshoring as an emerging contributor rather than an explanation for all of the current improvement.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 31, 2026 | Not available | Not available | Not available | Not available |
| Apr 30, 2026 | Not available | Not available | Not available | Not available |
| Jan 31, 2026 | Not available | Not available | Not available | Not available |
| Oct 31, 2025 | Not available | Not available | Not available | Not available |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $1.88B | $362M | $1.28 (diluted) |
| Q2 FY2026 | $1.83B | $339M | $1.19 (diluted) |
| Q1 FY2026 | $1.80B | $305M | $1.07 (diluted) |
| Q4 FY2025 | $1.86B | $434M | $1.53 (diluted) |
What are the financial strengths and risks for Agilent Technologies (A)?
Short answer
Cash and short-term investments were $0.00 at the Jul 31, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Agilent remains profitable and consistently generates positive operating cash flow, with the latest period showing a sharp cash-generation rebound. Cash and short-term investments have also increased over the reported span, while liquidity ratios indicate ample coverage of near-term obligations.
Debt nevertheless exceeds cash and investments, leaving Agilent in a net-debt position. That matters because the shares trade at a substantial earnings and sales valuation: weakening laboratory demand could pressure instrument revenue while selling and research costs continue, making sustained profit conversion more important than revenue growth alone. Distress and operating-quality screens are presently constructive, but they do not remove that valuation sensitivity.
What should you watch next at Agilent Technologies (A)?
Short answer · as of
The next earnings report is expected on Nov 23, 2026.
Research dated 2026-09-12.
Watch whether revenue and operating profit continue their recent sequential climb, whether operating cash flow holds near its stronger recent level, and whether another earnings report clears market expectations. A reversal in any of those measures would weaken the evidence that the recovery is broadening.
Management has supplied a more company-specific checkpoint: pharma reshoring orders are expected to become more meaningful around year-end, followed by revenue contribution later. The useful confirmation would be visible order momentum that ultimately reaches reported sales, while the upcoming report provides the nearer test of the raised outlook.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Agilent Technologies compare with its peers?
Short answer
Agilent Technologies's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Agilent combines complex analytical hardware with the supplies, software and services needed to keep laboratory workflows running. Compared with businesses dependent mainly on new equipment placements, CrossLab gives Agilent exposure to ongoing instrument use through columns, sample preparation, compliance, training and asset management.
Its diagnostics and genomics portfolio also reaches beyond analytical chemistry into tissue staining, genetic analysis and sequencing preparation. The relevant comparison is therefore not merely instrument breadth, but the mix of capital equipment, laboratory usage revenue and clinically oriented tools inside the same company.
| Company | Price | Market value | Score |
|---|---|---|---|
| $273.04 Oct 2, 2026 | $41.3B | 94 5-pillar Oct 4, 2026 | |
| $518.39 Oct 2, 2026 | $40.9B | 92 5-pillar Oct 4, 2026 | |
| $85.15 Oct 2, 2026 | $49.0B | 90 5-pillar Oct 4, 2026 | |
| $228.30 Oct 2, 2026 | $53.5B | 88 5-pillar Oct 4, 2026 | |
| Agilent Technologies (A) — this page | $167.77 | $47.4B | 84 |
| $1486.19 Oct 2, 2026 | $30.0B | 82 5-pillar Oct 4, 2026 | |
| $8.80 Oct 2, 2026 | $38.8B | 78 5-pillar Oct 4, 2026 | |
| $63.76 Oct 2, 2026 | $31.1B | 78 5-pillar Oct 4, 2026 | |
| $233.24 Oct 2, 2026 | $25.7B | 74 5-pillar Oct 4, 2026 | |
| $258.21 Oct 2, 2026 | $42.5B | 73 5-pillar Oct 4, 2026 | |
| $176.80 Oct 2, 2026 | $48.7B | 72 5-pillar Oct 4, 2026 | |
| $308.49 Oct 2, 2026 | $25.3B | 71 5-pillar Oct 4, 2026 | |
| $151.53 Oct 2, 2026 | $16.9B | 71 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $150.00 – $185.00
- Consensus target
- $170.00
- Median target
- $173.50
Consensus record · Captured .
Measured against a quoted price of $167.77 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 8, 2026
- Transactions
- 7
- Identified insiders
- 6
- Purchases
- 0
- Sales
- 2
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Agilent Technologies (A)?
Agilent Technologies Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why does Agilent CrossLab matter to Agilent’s business model?
CrossLab sells laboratory consumables and operational services rather than relying on new instrument purchases alone. Its position as Agilent’s largest disclosed segment makes ongoing laboratory activity a major part of the company’s revenue mix.
What do Agilent’s chromatography and mass spectrometry systems measure economically?
They represent laboratory capital demand, but they also create workflows that use columns, sample-preparation products, software and support. Agilent participates in both the equipment decision and the continuing operation of the laboratory.
Is pharma reshoring already the main driver of Agilent’s growth?
Management described the more meaningful order benefit as approaching around year-end and the revenue contribution as building later. The current recovery should therefore be judged on reported performance without treating the anticipated reshoring benefit as fully realized.
What would confirm that Agilent’s recent earnings recovery is durable?
Further revenue and operating-profit progression, continued positive cash generation and delivery against the raised outlook would strengthen the case. Order momentum from pharma reshoring would add a distinct source of confirmation beyond another expectations beat.
What is the A stock price today?
The last price recorded on this page for Agilent Technologies, Inc. (A) is $167.77, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the A price target?
The analyst consensus price target for Agilent Technologies, Inc. (A) is $170.00 (range $150.00 to $185.00, median $173.50), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are A's next earnings?
The next earnings date listed on this page for Agilent Technologies, Inc. (A) is Nov 23, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (26 figures)
The 26 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Santa Clara, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "5301 Stevens Creek Boulevard, Santa Clara, CA, 95051, US". |
FMP — 21 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $167.77 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T22:44:48.977Z. | |
px.change | Change on the day | +0.65% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $47.4B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T19:59:59.000Z. Captured from FMP at 2026-10-04T22:44:45.686Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$1.09 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q3 FY2026 | $1.88B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $108.35–$177.05 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 32.85 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.09M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.24 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Padraig McDonnell | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 18,200 | FMP | Financial Modeling Prep (FMP) company profile | |
fin.annual | Revenue and net result by fiscal year | 4 fiscal years, FY2022 through FY2025: FY2022 revenue $0.00, net result $0.00; FY2023 revenue $0.00, net result $0.00; FY2024 revenue $0.00, net result $0.00; FY2025 revenue $0.00, net result $0.00 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 53.7% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table | Quarterly income statement | 4 quarters through Q3 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. The market-value ratio is undefined when the reported amount is zero. | |
fin.total_debt | Total debt | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 6.43× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
earn.pt_range | Analyst price target, low to high | $150.00 – $185.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $170.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $173.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 7 transactions · 0 purchases, 2 sales, 5 other transactions · 6 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 8, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 23, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-08-29 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 84 of 100 · Exceptional · pillars 89 / 57 / 44 / 77 / 89 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 84 (stored snapshot Oct 3, 2026) → 84 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | AGILENT TECHNOLOGIES, INC. Our market-data provider lists the name as "Agilent Technologies, Inc."; the filer's own record is used here. | 2025-12-22 | OFFICIAL | SEC EDGAR — 10-K filed 2025-12-22 |
| Business description | Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Applied Markets: $1.31B; Agilent Cross Lab: $2.91B; Life Sciences and Applied Markets: $2.73B | 2025-10-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Management outlook — dated call excerpts | Captured record · 2 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-26 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research The company's SEC filings classify it under SIC 3826 — Laboratory Analytical Instruments. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-10-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-26 | FMP | Financial Modeling Prep (FMP) earnings |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $3.95B; Liquidity basis: cash and short-term investments; Total liabilities: $6.60B; Cash and short-term investments: $1.76B; Cash and investments: $1.89B; Long-term investments: $130.00M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.89B; Cash and short-term investments: $1.76B; Long-term investments: $130.00M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-07-31 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-07-31; Cash basis: cash and short-term investments; Net cash: -$2.19B; Total debt: $3.95B; Cash and investments: $1.76B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-07-31 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 1.56; Current ratio: 2.05; Debt to equity: 0.54; Net margin: 19.5%; Gross margin: 53.7%; Operating margin: 22.2%; Return on assets: 10.3%; Return on equity: 20.5% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 5.02; Piotroski F-score: 6 Altman Z below 1.8 is the conventional distress zone. For a company holding large cash against negative retained earnings the score mostly reflects the retained-earnings term. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2026-11-23; EPS estimate: $1.72 per share; Revenue estimate: $1.99B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.
ETFs that hold A
Funds in our ETF coverage that list A among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Madison Covered Call ETF (CVRD) | 3.18% |